Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

NCT00691652 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Funding ended when only one subject enrolled and subject withdrew early.

Conditions

Lymphoma

Interventions

BIOLOGICAL: rituximab
DRUG: clofarabine
GENETIC: DNA methylation analysis
GENETIC: gene expression analysis
GENETIC: microarray analysis
GENETIC: polymerase chain reaction
OTHER: high performance liquid chromatography
OTHER: laboratory biomarker analysis

Sponsor

OHSU Knight Cancer Institute

Collaborators

[object Object]